SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Liesveld Jane)
 

Search: WFRF:(Liesveld Jane) > Comparison of outco...

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS

Gupta, Vikas (author)
Princess Margaret Canc Ctr, 700 Univ Ave,6-326, Toronto, ON M5G 1Z5, Canada.
Kim, Soyoung (author)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA.
Hu, Zhen-Huan (author)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.
show more...
Liu, Ying (author)
Columbia Univ, Dept Psychiat, Mental Hlth Data Sci, Irving Med Ctr, New York, NY USA.
Aljurf, Mahmoud (author)
King Faisal Specialist Hosp Ctr & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia.
Bacher, Ulrike (author)
Univ Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland.
Beitinjaneh, Amer (author)
Univ Miami, Div Transplantat & Cellular Therapy, Miami, FL USA.
Cahn, Jean-Yves (author)
Ctr Hosp Univ CHU Grenoble Alpes, Dept Hematol, Grenoble, France.
Cerny, Jan (author)
Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.
Copelan, Edward (author)
Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.
Gadalla, Shahinaz M. (author)
NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA.
Gale, Robert Peter (author)
Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.
Ganguly, Siddhartha (author)
Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.
George, Biju (author)
Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
Gerds, Aaron T. (author)
Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA.
Gergis, Usama (author)
Thomas Jefferson Univ, Div Hematol Malignancies, Dept Med Oncol, Philadelphia, PA 19107 USA.
Hamilton, Betty K. (author)
Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.
Hashmi, Shahrukh (author)
Mayo Clin, Dept Internal Med, Rochester, MN USA.;King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi Arabia.
Hildebrandt, Gerhard C. (author)
Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
Kamble, Rammurti T. (author)
Baylor Univ, Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX USA.
Kindwall-Keller, Tamila (author)
Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA.
Lazarus, Hillard M. (author)
Case Western Reserve Univ, Cleveland Med Ctr, Univ Hosp, Cleveland, OH 44106 USA.
Liesveld, Jane L. (author)
Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.
Litzow, Mark (author)
Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA.
Maziarz, Richard T. (author)
Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA.
Nishihori, Taiga (author)
H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.
Olsson, Richard (author)
Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden
Rizzieri, David (author)
Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.
Savani, Bipin N. (author)
Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
Seo, Sachiko (author)
Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.
Solh, Melhem (author)
Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
Szer, Jeff (author)
Royal Melbourne Hosp, Clin Haematol, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Verdonck, Leo F. (author)
Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands.
Wirk, Baldeep (author)
Penn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA.
Woolfrey, Ann (author)
Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
Yared, Jean A. (author)
Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA.
Alyea, Edwin P. (author)
Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA.
Popat, Uday R. (author)
Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX 77030 USA.
Sobecks, Ronald M. (author)
Cleveland Clin, Hematol & Med Oncol, Cleveland, OH 44106 USA.
Scott, Bart L. (author)
Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
Nakamura, Ryotaro (author)
City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.
Saber, Wael (author)
Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.
show less...
Princess Margaret Canc Ctr, 700 Univ Ave,6-326, Toronto, ON M5G 1Z5, Canada Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA. (creator_code:org_t)
2020-10-02
2020
English.
In: Blood Advances. - : American Society of Hematology. - 2473-9529 .- 2473-9537. ; 4:19, s. 4748-4757
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL12 myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [ CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view